Tamer M Fouad, MD, PhD - National Cancer Institute, Cairo University - Faculty Fellow

Tamer M Fouad

MD, PhD

National Cancer Institute, Cairo University

Faculty Fellow

Cairo | Egypt

Main Specialties: Oncology

Additional Specialties: Oncology

Tamer M Fouad, MD, PhD - National Cancer Institute, Cairo University - Faculty Fellow

Tamer M Fouad

MD, PhD

Introduction

Primary Affiliation: National Cancer Institute, Cairo University - Cairo , Egypt

Specialties:

Additional Specialties:

Publications

24Publications

449Reads

-Profile Views

76PubMed Central Citations

The 'indirect costs' of underfunding foreign partners in global health research: A case study.

Glob Public Health 2018 Oct 16;13(10):1422-1429. Epub 2017 Sep 16.

f Oregon Health Sciences University-Portland State University School of Public Health , Portland , OR , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17441692.2017.1372504DOI Listing
October 2018
9 Reads
3 Citations

Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.

Breast Cancer Res Treat 2018 Sep 18;171(2):501-511. Epub 2018 Jun 18.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-4853-4DOI Listing
September 2018
14 Reads
3.940 Impact Factor

Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.

Surg Clin North Am 2018 Aug 24;98(4):787-800. Epub 2018 May 24.

Morgan Welch Inflammatory Breast Cancer Research and Clinic Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suc.2018.03.009DOI Listing
August 2018
6 Reads
1.880 Impact Factor

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.

Ther Adv Med Oncol 2018 30;10:1758835918786858. Epub 2018 Jul 30.

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918786858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066809PMC
July 2018
32 Reads

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Mod Pathol 2016 Apr 26;29(4):330-46. Epub 2016 Feb 26.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2016.38DOI Listing
April 2016
52 Reads
4 Citations
6.190 Impact Factor

Trends in Metastatic Breast and Prostate Cancer.

Authors:
Tamer M Fouad

N Engl J Med 2016 02;374(6):595

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1515983DOI Listing
February 2016
2 Reads
55.873 Impact Factor

High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.

Oncologist 2016 Jan 9;21(1):21-7. Epub 2015 Dec 9.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709200PMC
January 2016
30 Reads
4 Citations
4.870 Impact Factor

Survival of patients with metastatic breast cancer with or without locoregional therapy.

Authors:
Tamer M Fouad

Lancet Oncol 2015 Dec;16(16):e585-6

Department of Medical Oncology, National Cancer Institute, Cairo 11796, Egypt. Electronic address:

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451500445
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)00445-3DOI Listing
December 2015
3 Reads
24.690 Impact Factor

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Breast 2015 Nov 5;24 Suppl 2:S143-8. Epub 2015 Aug 5.

Institut Jules Bordet, Université Libre des Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.034DOI Listing
November 2015
33 Reads
10 Citations
2.381 Impact Factor

Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients.

Ann Oncol 2015 Jul 21;26(7):1511. Epub 2015 Apr 21.

Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdv193DOI Listing
July 2015
3 Reads
7.040 Impact Factor

Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers.

Clin Breast Cancer 2015 Feb 15;15(1):37-42. Epub 2014 Aug 15.

Department of Breast Medical Oncology, The University Texas MD Anderson Cancer Center, Houston, TX; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2014.06.007DOI Listing
February 2015
68 Reads
2.110 Impact Factor

Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Breast Cancer Res 2015 Jan 9;17. Epub 2015 Jan 9.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-014-0507-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318180PMC
January 2015
21 Reads
8 Citations

The role of inflammation in inflammatory breast cancer.

Adv Exp Med Biol 2014 ;816:53-73

Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-0348-0837-8_3DOI Listing
September 2014
8 Reads
17 Citations

Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.

Target Oncol. 2014 May 27

Targeted Oncology

Cetuximab-containing treatments for metastatic colorectal cancer have been shown to have higher overall response rates and longer progression-free and overall survival than other systemic therapies. Cetuximab-related manifestations, including severe skin toxicity and early tumor shrinkage, have been shown to be predictors of response to cetuximab. We hypothesized that early skin toxicity is a predictor of response and better outcomes in patients with advanced colorectal carcinoma. We retrospectively evaluated 62 patients with colorectal adenocarcinoma who had unresectable tumors and were treated with cetuximab in our institution. Skin toxicity grade was evaluated on each treatment day. Tumor size was evaluated using computed tomography prior to treatment and 4-8 weeks after the start of treatment with cetuximab.Patients with early tumor shrinkage after starting treatment with cetuximab had a significantly higher overall response rate (P = 0.0001). Patients with early skin toxicity showed significantly longer overall survival (P = 0.0305), and patients with higher skin toxicity grades had longer progression-free survival (P = 0.0168).We have shown that early tumor shrinkage, early onset of skin toxicity, and high skin toxicity grade are predictors of treatment efficacy and/or outcome in patients with advanced colorectal carcinoma treated with cetuximab.

View Article
May 2014
1 Read

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes

Ann Oncol. 2014 Feb;25(2):384-91.

Annals of Oncology

BACKGROUND: Subtypes defined by hormonal receptor (HR) and HER2 status have not been well studied in inflammatory breast cancer (IBC). We characterized clinical parameters and long-term outcomes, and compared pathological complete response (pCR) rates by HR/HER2 subtype in a large IBC patient population. We also compared disease-free survival (DFS) and overall survival (OS) between IBC patients who received targeted therapies (anti-hormonal, anti-HER2) and those who did not. PATIENTS AND METHODS: We retrospectively reviewed the records of patients diagnosed with IBC and treated at MD Anderson Cancer Center from January 1989 to January 2011. Of those, 527 patients had received neoadjuvant chemotherapy and had available information on estrogen receptor (ER), progesterone receptor (PR), and HER2 status. HR status was considered positive if either ER or PR status was positive. Using the Kaplan-Meier method, we estimated median DFS and OS durations from the time of definitive surgery. Using the Cox proportional hazards regression model, we determined the effect of prognostic factors on DFS and OS. Results were compared by subtype. RESULTS: The overall pCR rate in stage III IBC was 15.2%, with the HR-positive/HER2-negative subtype showing the lowest rate (7.5%) and the HR-negative/HER2-positive subtype, the highest (30.6%). The HR-negative, HER2-negative subtype (triple-negative breast cancer, TNBC) had the worst survival rate. HR-positive disease, irrespective of HER2 status, had poor prognosis that did not differ from that of the HR-negative/HER2-positive subtype with regard to OS or DFS. Achieving pCR, no evidence of vascular invasion, non-TNBC, adjuvant hormonal therapy, and radiotherapy were associated with longer DFS and OS. CONCLUSIONS: Hormone receptor and HER2 molecular subtypes had limited predictive and prognostic power in our IBC population. All molecular subtypes of IBC had a poor prognosis. HR-positive status did not necessarily confer a good prognosis. For all IBC subtypes, novel, specific treatment strategies are needed in the neoadjuvant and adjuvant settings.

View Article
February 2014

Acute myeloid leukemia developing in patients with autoimmune diseases.

Haematologica 2012 Jun 16;97(6):805-17. Epub 2011 Dec 16.

Department of Medical Oncology, NCI-Cairo University, 11796 Cairo, Egypt.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2011.056283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366644PMC
June 2012
1 Read
11 Citations
5.870 Impact Factor

Acute leukemia in women.

Womens Health (Lond) 2010 Mar;6(2):239-49

Department of Biopathology, University of TorVergata, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/whe.10.4DOI Listing
March 2010
13 Reads
1 Citation

Top co-authors

Naoto T Ueno
Naoto T Ueno

The University of Texas MD Anderson Cancer Center

13
Ricardo H Alvarez
Ricardo H Alvarez

The University of Texas MD Anderson Cancer Center

8
Vicente Valero
Vicente Valero

The University of Texas MD Anderson Cancer Center

8
Takahiro Kogawa
Takahiro Kogawa

Sapporo Medical University School of Medicine

7
Hiroko Masuda
Hiroko Masuda

Gunma University Graduate School of Medicine

6
Wendy A Woodward
Wendy A Woodward

The University of Texas MD Anderson Cancer Center

6
Diane D Liu
Diane D Liu

The University of Texas M. D. Anderson Cancer Center

5
Randa El-Zein
Randa El-Zein

The University of Texas M.D. Anderson Cancer Center

4
James M Reuben
James M Reuben

The University of Texas MD Anderson Cancer Center

4
Anthony Lucci
Anthony Lucci

The University of Texas MD Anderson Cancer Center

4